Share on StockTwits

Tekmira Pharmaceuticals (NASDAQ:TKMR) was the recipient of some unusual options trading activity on Monday. Traders acquired 8,573 call options on the company, Analyst Ratings.Net reports. This is an increase of 1,207% compared to the average daily volume of 656 call options.

Several analysts have recently commented on the stock. Analysts at Clarus initiated coverage on shares of Tekmira Pharmaceuticals in a research note on Thursday. They set a “buy” rating and a $22.50 price target on the stock. Separately, analysts at Maxim Group cut their price target on shares of Tekmira Pharmaceuticals from $29.00 to $23.00 in a research note on Wednesday, June 4th. They now have a “buy” rating on the stock. Finally, analysts at Stifel Nicolaus reiterated a “buy” rating on shares of Tekmira Pharmaceuticals in a research note on Thursday, May 15th. They now have a $31.00 price target on the stock, down previously from $37.00. One research analyst has rated the stock with a sell rating and four have issued a buy rating to the company. Tekmira Pharmaceuticals presently has an average rating of “Buy” and an average price target of $26.63.

Shares of Tekmira Pharmaceuticals (NASDAQ:TKMR) traded down 7.01% during mid-day trading on Monday, hitting $13.26. 9,875,691 shares of the company’s stock traded hands. Tekmira Pharmaceuticals has a 52-week low of $5.08 and a 52-week high of $31.48. The stock has a 50-day moving average of $11.8 and a 200-day moving average of $15.61.

Tekmira Pharmaceuticals Corporation is a biopharmaceutical company focused on advancing ribonucleic acid (NASDAQ:TKMR) interference (RNAi) therapeutics and providing its lipid nanoparticle (LNP) delivery technology to pharmaceutical partners.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.